Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab.

Kunal S PatelSameer KejriwalSamasuk ThammachanthaCourtney DuongAdrian MurilloLynn K GordonTimothy F CloughesyLinda LiauWilliam YongIsaac YangMadhuri Wadehra

Published in: Neuro-oncology advances (2020)

Bevacizumab treatment increased EMP2 protein expression. This increase in EMP2 correlated with reduced mean survival time post-bevacizumab therapy. We hypothesize a role of EMP2 in clinical bevacizumab resistance and as a potential antiangiogenic therapeutic target in glioblastoma.

Keyphrases

metastatic colorectal cancer
stem cells
risk assessment
climate change
bone marrow
replacement therapy